Top

06-26-2018 | Devices and technology | Review | Article

Technology in the management of type 1 diabetes mellitus — current status and future prospects

Journal: Nature Reviews Endocrinology

Authors: Martin Tauschmann, Roman Hovorka

Publisher: Nature Publishing Group UK

Abstract

Type 1 diabetes mellitus (T1DM) represents 5–10% of diabetes cases worldwide. The incidence of T1DM is increasing, and there is no immediate prospect of a cure. As such, lifelong management is required, the burden of which is being eased by novel treatment modalities, particularly from the field of diabetes technologies. Continuous glucose monitoring has become the standard of care and includes factory-calibrated subcutaneous glucose monitoring and long-term implantable glucose sensing. In addition, considerable progress has been made in technology-enabled glucose-responsive insulin delivery. The first hybrid insulin-only closed-loop system has been commercialized, and other closed-loop systems are under development, including dual-hormone glucose control systems. This Review focuses on well-established diabetes technologies, including glucose sensing, pen-based insulin delivery, data management and data analytics. We also cover insulin pump therapy, threshold-based suspend, predictive low-glucose suspend and single-hormone and dual-hormone closed-loop systems. Clinical practice recommendations for insulin pump therapy and continuous glucose monitoring are presented, and ongoing research and future prospects are highlighted. We conclude that the management of T1DM is improved by diabetes technology for the benefit of the majority of people with T1DM, their caregivers and guardians and health-care professionals treating patients with T1DM.

International Diabetes Federation. Diabetes Atlas (7th edition). http://www.diabetesatlas.org (2015).

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).CrossRef

Paton, J. S., Wilson, M., Ireland, J. T. & Reith, S. B. Convenient pocket insulin syringe. Lancet 1, 189–190 (1981).PubMedCrossRef

Pickup, J. C., Keen, H., Parsons, J. A. & Alberti, K. G. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br. Med. J. 1, 204–207 (1978).PubMedPubMedCentralCrossRef

Renard, E. Insulin pump use in Europe. Diabetes Technol. Ther. 12 (Suppl. 1), S29–S32 (2010).PubMedCrossRef

Szypowska, A. et al. Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry. Pediatr. Diabetes 17 (Suppl. 23), 38–45 (2016).PubMedCrossRef

Sherr, J. L. et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia 59, 87–91 (2016).PubMedCrossRef

Zisser, H. C. The OmniPod Insulin Management System: the latest innovation in insulin pump therapy. Diabetes Ther. 1, 10–24 (2010).PubMedPubMedCentralCrossRef

Leelarathna, L. et al. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. Diabet. Med. 34, 1372–1379 (2017).PubMedCrossRef

10.

Ramotowska, A., Golicki, D., Dzygalo, K. & Szypowska, A. The effect of using the insulin pump bolus calculator compared to standard insulin dosage calculations in patients with type 1 diabetes mellitus — systematic review. Exp. Clin. Endocrinol. Diabetes 121, 248–254 (2013).PubMedCrossRef

11.

Jones, S. M., Quarry, J. L., Caldwell-McMillan, M., Mauger, D. T. & Gabbay, R. A. Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. Diabetes Technol. Ther. 7, 233–240 (2005).PubMedCrossRef

12.

O’Connell, M. A., Gilbertson, H. R., Donath, S. M. & Cameron, F. J. Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy: impact of glycemic index and prandial bolus type. Diabetes Care 31, 1491–1495 (2008).PubMedPubMedCentralCrossRef

13.

Pickup, J. C. & Sutton, A. J. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet. Med. 25, 765–774 (2008).PubMedCrossRef

14.

Yeh, H. C. et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann. Intern. Med. 157, 336–347 (2012).PubMedCrossRef

15.

Jeitler, K. et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 51, 941–951 (2008).PubMedCrossRef

16.

Fatourechi, M. M. et al. Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J. Clin. Endocrinol. Metab. 94, 729–740 (2009).PubMedCrossRef

17.

Monami, M., Lamanna, C., Marchionni, N. & Mannucci, E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol. 47 (Suppl. 1), 77–81 (2010).PubMedCrossRef

18.

Pankowska, E., Błazik, M., Dziechciarz, P., Szypowska, A. & Szajewska, H. Continuous subcutaneous insulin infusion versus multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr. Diabetes 10, 52–58 (2009).CrossRef

19.

Blazik, M. & Pankowska, E. The effect of bolus and food calculator Diabetics on glucose variability in children with type 1 diabetes treated with insulin pump: the results of RCT. Pediatr. Diabetes 13, 534–539 (2012).PubMedCrossRef

20.

Beato-Víbora, P. et al. Sustained benefit of continuous subcutaneous insulin infusion on glycaemic control and hypoglycaemia in adults with Type 1 diabetes. Diabet. Med. 32, 1453–1459 (2015).PubMedCrossRef

21.

Joubert, M. et al. Cross-sectional survey and retrospective analysis of a large cohort of adults with type 1 diabetes with long-term continuous subcutaneous insulin infusion treatment. J. Diabetes Sci. Technol. 8, 1005–1010 (2014).PubMedPubMedCentralCrossRef

22.

Orr, C. J., Hopman, W., Yen, J. L. & Houlden, R. L. Long-term efficacy of insulin pump therapy on glycemic control in adults with type 1 diabetes mellitus. Diabetes Technol. Ther. 17, 49–54 (2015).PubMedCrossRef

23.

Johnson, S. R., Cooper, M. N., Jones, T. W. & Davis, E. A. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia 56, 2392–2400 (2013).PubMedCrossRef

24.

Steineck, I. et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. BMJ 350, h3234 (2015).PubMedPubMedCentralCrossRef

25.

Karges, B. et al. Association of insulin pump therapy versus insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA 318, 1358–1366 (2017).PubMedPubMedCentralCrossRef

26.

Lin, M. H. et al. Race, socioeconomic status, and treatment center are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. Diabetes Technol. Ther. 15, 929–934 (2013).PubMedPubMedCentralCrossRef

27.

Khanolkar, A. R. et al. Young people with Type 1 diabetes of non-white ethnicity and lower socio-economic status have poorer glycaemic control in England and Wales. Diabet. Med. 33, 1508–1515 (2016).PubMedCrossRef

28.

American Diabetes Association. Standards of medical care in diabetes — 2017. Diabetes Care 40 (Suppl. 1), S1–S135 (2017).

29.

Rewers, M. J. et al. ISPAD clinical practice consensus guidelines 2014. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr. Diabetes 15 (Suppl. 20), 102–114 (2014).PubMedCrossRef

30.

Ziegler, R. et al. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr. Diabetes 12, 11–17 (2011).PubMedCrossRef

31.

Miller, K. M. et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care 36, 2009–2014 (2013).PubMedPubMedCentralCrossRef

32.

Ziegler, R. et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care 36, 3613–3619 (2013).PubMedPubMedCentralCrossRef

33.

Vallejo Mora, M. D. R. et al. Bolus calculator reduces hypoglycemia in the short term and fear of hypoglycemia in the long term in subjects with type 1 diabetes (CBMDI study). Diabetes Technol. Ther. 19, 402–409 (2017).PubMedPubMedCentralCrossRef

34.

Vallejo-Mora, M. D. et al. The Calculating Boluses on Multiple Daily Injections (CBMDI) study: a randomized controlled trial on the effect on metabolic control of adding a bolus calculator to multiple daily injections in people with type 1 diabetes. J. Diabetes 9, 24–33 (2017).PubMedCrossRef

35.

Bailey, T., Bode, B. W., Christiansen, M. P., Klaff, L. J. & Alva, S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol. Ther. 17, 787–794 (2015).PubMedPubMedCentralCrossRef

36.

Kropff, J. et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care 40, 63–68 (2017).PubMedCrossRef

37.

Bergenstal, R. M. Continuous glucose monitoring: transforming diabetes management step by step. Lancet 391, 1334–1336 (2018).PubMedCrossRef

38.

DeSalvo, D. et al. Continuous glucose monitoring (CGM) and glycemic control among youth with type 1 diabetes (T1D): international comparison from the T1D Exchange (T1DX) and the DPV Initiative. 43rd Annual Conference of the International Society for Pediatric and Adolescent Diabetes, Innsbruck, Austria (2017).

39.

Bailey, T. S., Chang, A. & Christiansen, M. Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J. Diabetes Sci. Technol. 9, 209–214 (2015).PubMedCrossRef

40.

Laffel, L. Improved accuracy of continuous glucose monitoring systems in pediatric patients with diabetes mellitus: results from two studies. Diabetes Technol. Ther. 18 (Suppl. 2), S223–S233 (2016).PubMedCrossRef

41.

Garg, S. K. et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol. Ther. 19, 155–163 (2017).PubMedPubMedCentralCrossRef

42.

Kropff, J. et al. Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions. Diabetes Obes. Metab. 17, 343–349 (2015).PubMedCrossRef

43.

Pleus, S. et al. Rate-of-change dependence of the performance of two CGM systems during induced glucose swings. J. Diabetes Sci. Technol. 9, 801–807 (2015).PubMedPubMedCentralCrossRef

44.

Kovatchev, B. P., Patek, S. D., Ortiz, E. A. & Breton, M. D. Assessing sensor accuracy for non-adjunct use of continuous glucose monitoring. Diabetes Technol. Ther. 17, 177–186 (2015).PubMedPubMedCentralCrossRef

45.

Aleppo, G. et al. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 40, 538–545 (2017).PubMedPubMedCentralCrossRef

46.

Agiostratidou, G. et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 40, 1622–1630 (2017).PubMedCrossRef

47.

Danne, T. et al. International consensus on use of continuous glucose monitoring. Diabetes Care 40, 1631–1640 (2017).PubMedCrossRef

48.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N. Engl. J. Med. 359, 1464–1476 (2008).CrossRef

49.

Pickup, J. C., Freeman, S. C. & Sutton, A. J. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 343, d3805 (2011).PubMedPubMedCentralCrossRef

50.

Langendam, M. et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst. Rev. 1, Cd008101 (2012).PubMed

51.

Szypowska, A., Ramotowska, A., Dzygalo, K. & Golicki, D. Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials. Eur. J. Endocrinol. 166, 567–574 (2012).PubMedCrossRef

52.

Hoeks, L. B., Greven, W. L. & de Valk, H. W. Real-time continuous glucose monitoring system for treatment of diabetes: a systematic review. Diabet. Med. 28, 386–394 (2011).PubMedCrossRef

53.

Golicki, D. T., Golicka, D., Groele, L. & Pankowska, E. Continuous glucose monitoring system in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetologia 51, 233–240 (2008).PubMedCrossRef

54.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 33, 17–22 (2010).CrossRef

55.

Bergenstal, R. M. et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N. Engl. J. Med. 363, 311–320 (2010).PubMedCrossRef

56.

Bergenstal, R. M. et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care 34, 2403–2405 (2011).PubMedPubMedCentralCrossRef

57.

Battelino, T. et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 34, 795–800 (2011).PubMedPubMedCentralCrossRef

58.

Battelino, T. et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 55, 3155–3162 (2012).PubMedPubMedCentralCrossRef

59.

Beck, R. W. et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 317, 371–378 (2017).PubMedCrossRef

60.

Fonseca, V. A. et al. Continuous glucose monitoring: a consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr. Pract. 22, 1008–1021 (2016).PubMedCrossRef

61.

Foster, N. C. et al. Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care 39, e81–e82 (2016).PubMedPubMedCentralCrossRef

62.

Lind, M. et al. Continuous glucose monitoring versus conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 317, 379–387 (2017).PubMedCrossRef

63.

Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J. & Weitgasser, R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388, 2254–2263 (2016).PubMedCrossRef

64.

Edge, J. et al. An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Arch. Dis. Child 102, 543–549 (2017).PubMedPubMedCentralCrossRef

65.

Ish-Shalom, M., Wainstein, J., Raz, I. & Mosenzon, O. Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device. J. Diabetes Sci. Technol. 10, 1412–1413 (2016).PubMedPubMedCentralCrossRef

66.

Dover, A. R., Stimson, R. H., Zammitt, N. N. & Gibb, F. W. Flash glucose monitoring improves outcomes in a type 1 diabetes clinic. J. Diabetes Sci. Technol. 11, 442–443 (2017).PubMedPubMedCentralCrossRef

67.

McKnight, J. A. & Gibb, F. W. Flash glucose monitoring is associated with improved glycaemic control but use is largely limited to more affluent people in a UK diabetes centre. Diabet. Med. 34, 732 (2017).PubMedCrossRef

68.

Reddy, M. et al. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet. Med. 35, 483–490 (2018).PubMedCrossRef

69.

Dunn, T. C., Xu, Y., Hayter, G. & Ajjan, R. A. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res. Clin. Pract. 137, 37–46 (2018).PubMedCrossRef

70.

Ly, T. T. et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension versus standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 310, 1240–1247 (2013).PubMedCrossRef

71.

Bergenstal, R. M. et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N. Engl. J. Med. 369, 224–232 (2013).PubMedCrossRef

72.

Weiss, R. et al. Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE in-home study. Diabetes Technol. Ther. 17, 542–547 (2015).PubMedPubMedCentralCrossRef

73.

Danne, T. et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol. Ther. 13, 1129–1134 (2011).PubMedCrossRef

74.

Choudhary, P. et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 34, 2023–2025 (2011).PubMedPubMedCentralCrossRef

75.

Agrawal, P., Zhong, A., Welsh, J. B., Shah, R. & Kaufman, F. R. Retrospective analysis of the real-world use of the threshold suspend feature of sensor-augmented insulin pumps. Diabetes Technol. Ther. 17, 316–319 (2015).PubMedPubMedCentralCrossRef

76.

Maahs, D. M. et al. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care 37, 1885–1891 (2014).PubMedPubMedCentralCrossRef

77.

Buckingham, B. A. et al. Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis. Diabetes Care 38, 1197–1204 (2015).PubMedPubMedCentralCrossRef

78.

Battelino, T., Nimri, R., Dovc, K., Phillip, M. & Bratina, N. Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. Diabetes Care 40, 764–770 (2017).PubMedCrossRef

79.

Steil, G. M., Rebrin, K., Darwin, C., Hariri, F. & Saad, M. F. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 55, 3344–3350 (2006).PubMedCrossRef

80.

Weinzimer, S. A. et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31, 934–939 (2008).PubMedCrossRef

81.

Hovorka, R. et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 375, 743–751 (2010).PubMedCrossRef

82.

Atlas, E., Nimri, R., Miller, S., Grunberg, E. A. & Phillip, M. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 33, 1072–1076 (2010).PubMedPubMedCentralCrossRef

83.

El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G. & Damiano, E. R. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci. Transl Med. 2, 27ra27 (2010).PubMedPubMedCentralCrossRef

84.

Bakhtiani, P. A., Zhao, L. M., El Youssef, J., Castle, J. R. & Ward, W. K. A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy. Diabetes Obes. Metab. 15, 1065–1070 (2013).PubMedCrossRef

85.

Weisman, A., Bai, J. W., Cardinez, M., Kramer, C. K. & Perkins, B. A. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 5, 501–512 (2017).PubMedCrossRef

86.

Thabit, H. et al. Home use of an artificial beta cell in type 1 diabetes. N. Engl. J. Med. 373, 2129–2140 (2015).PubMedPubMedCentralCrossRef

87.

Kropff, J. et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol. 3, 939–947 (2015).PubMedCrossRef

88.

Bergenstal, R. M. et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316, 1407–1408 (2016).PubMedCrossRef

89.

Garg, S. K. et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N. Engl. J. Med. 377, 2337–2348 (2017).PubMedCrossRef

90.

Lewis, D. OpenAPS. https://openaps.org/ (2017).

91.

Lewis, D., Leibrand, S. & OpenAPS Community. Real-world use of open source artificial pancreas systems. J. Diabetes Sci. Technol. 10, 1411 (2016).PubMedPubMedCentralCrossRef

92.

Duke, D. C. et al. Distal technologies and type 1 diabetes management. Lancet Diabetes Endocrinol. 6, 143–156 (2018).PubMedCrossRef

93.

Mazze, R. S. et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol. Ther. 10, 149–159 (2008).PubMedCrossRef

94.

Wong, J. C., Neinstein, A. B., Spindler, M. & Adi, S. A minority of patients with type 1 diabetes routinely downloads and retrospectively reviews device data. Diabetes Technol. Ther. 17, 555–562 (2015).PubMedPubMedCentralCrossRef

95.

Beck, R. W. Downloading diabetes device data: empowering patients to download at home to achieve better outcomes. Diabetes Technol. Ther. 17, 536–537 (2015).PubMedCrossRef

96.

Lee, J. M. et al. Real-world use and self-reported health outcomes of a patient-designed do-it-yourself mobile technology system for diabetes: lessons for mobile health. Diabetes Technol. Ther. 19, 209–219 (2017).PubMedCrossRef

97.

Lee, J. M., Hirschfeld, E. & Wedding, J. A patient-designed do-it-yourself mobile technology system for diabetes: promise and challenges for a new era in medicine. JAMA 315, 1447–1448 (2016).PubMedCrossRef

98.

Trawley, S. et al. The use of mobile applications among adolescents with type 1 diabetes: results from Diabetes MILES Youth-Australia. Diabetes Technol. Ther. 18, 813–819 (2016).PubMedCrossRef

99.

Frøisland, D. H., Arsand, E. & Skårderud, F. Improving diabetes care for young people with type 1 diabetes through visual learning on mobile phones: mixed-methods study. J. Med. Internet Res. 14, e111 (2012).PubMedPubMedCentralCrossRef

100.

Hanauer, D. A., Wentzell, K., Laffel, N. & Laffel, L. M. Computerized Automated Reminder Diabetes System (CARDS): e-mail and SMS cell phone text messaging reminders to support diabetes management. Diabetes Technol. Ther. 11, 99–106 (2009).PubMedPubMedCentralCrossRef

101.

Cafazzo, J. A., Casselman, M., Hamming, N., Katzman, D. K. & Palmert, M. R. Design of an mHealth app for the self-management of adolescent type 1 diabetes: a pilot study. J. Med. Internet Res. 14, e70 (2012).PubMedPubMedCentralCrossRef

102.

Goyal, S. et al. A mobile app for the self-management of type 1 diabetes among adolescents: a randomized controlled trial. JMIR Mhealth Uhealth 5, e82 (2017).PubMedPubMedCentralCrossRef

103.

Neinstein, A. et al. A case study in open source innovation: developing the Tidepool Platform for interoperability in type 1 diabetes management. J. Am. Med. Inform. Assoc. 23, 324–332 (2016).PubMedCrossRef

104.

Hou, C., Carter, B., Hewitt, J., Francisa, T. & Mayor, S. Do mobile phone applications improve glycemic control (HbA1c) in the self-management of diabetes? A systematic review, meta-analysis, and GRADE of 14 randomized trials. Diabetes Care 39, 2089–2095 (2016).PubMedCrossRef

105.

Wu, Y. et al. Mobile app-based interventions to support diabetes self-management: a systematic review of randomized controlled trials to identify functions associated with glycemic efficacy. JMIR Mhealth Uhealth 5, e35 (2017).PubMedPubMedCentralCrossRef

106.

Bailey, T. S. et al. American Assiciation of Clinical Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring consensus statement. Endocr. Pract. 22, 231–261 (2016).PubMedCrossRef

107.

Grunberger, G. et al. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr. Pract. 20, 463–489 (2014).PubMedCrossRef

108.

Klonoff, D. C. et al. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 96, 2968–2979 (2011).PubMedCrossRef

109.

Peters, A. L. et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 3922–3937 (2016).PubMedCrossRef

110.

Danne, T. et al. ISPAD clinical practice consensus guidelines 2014. Insulin treatment in children and adolescents with diabetes. Pediatr. Diabetes 15 (Suppl. 20), 115–134 (2014).PubMedCrossRef

111.

National Institute for Health and Care Excellence. NICE guideline (NG) 18, diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE http://nice.org.uk/guidance/ng18 (2015).

112.

National Institute for Health and Care Excellence. NICE guideline (NG) 17, type 1 diabetes in adults: diagnosis and management. NICE http://nice.org.uk/guidance/ng17 (2015).

113.

National Institute for Health and Care Excellence. Technology appraisal guidance (TA151). Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. NICE nice.org.uk/guidance/ta151 (2008).

114.

National Institute for Health and Care Excellence. Diagnostics guidance (DG21). Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system). NICE nice.org.uk/guidance/dg21 (2016).

115.

Edelman, S. V. Regulation catches up to reality. J. Diabetes Sci. Technol. 11, 160–164 (2017).PubMedCrossRef

116.

Pettus, J. & Edelman, S. V. Recommendations for using real-time continuous glucose monitoring (rtCGM) data for insulin adjustments in type 1 diabetes. J. Diabetes Sci. Technol. 11, 138–147 (2017).PubMedCrossRef

117.

Castle, J. R. & Jacobs, P. G. Nonadjunctive use of continuous glucose monitoring for diabetes treatment decisions. J. Diabetes Sci. Technol. 10, 1169–1173 (2016).PubMedPubMedCentralCrossRef

118.

Forlenza, G. P., Argento, N. B. & Laffel, L. M. Practical considerations on the use of continuous glucose monitoring in pediatrics and older adults and nonadjunctive use. Diabetes Technol. Ther. 19 (S3), S13–S20 (2017).PubMedCrossRef

119.

National Institute for Health and Care Excellence. FreeStyle Libre for glucose monitoring. Medtech innovation briefing. NICE http://nice.org.uk/guidance/mib110 (2017).

120.

Wang, Y. et al. “Learning” can improve the blood glucose control performance for type 1 diabetes mellitus. Diabetes Technol. Ther. 19, 41–48 (2017).PubMedCrossRef

121.

Dassau, E. et al. Adjustment of open-loop settings to improve closed-loop results in type 1 diabetes: a multicenter randomized trial. J. Clin. Endocrinol. Metab. 100, 3878–3886 (2015).PubMedPubMedCentralCrossRef

122.

Reddy, M. et al. Clinical safety and feasibility of the advanced bolus calculator for type 1 diabetes based on case-based reasoning: a 6-week nonrandomized single-arm pilot study. Diabetes Technol. Ther. 18, 487–493 (2016).PubMedCrossRef

123.

Klonoff, D. C. & Fellow AIMBE. Trends in FDA regulation of software to control insulin dosing. J. Diabetes Sci. Technol. 9, 503–506 (2015).PubMedPubMedCentralCrossRef

124.

Bally, L., Thabit, H. & Hovorka, R. Finding the right route for insulin delivery — an overview of implantable pump therapy. Expert Opin. Drug Deliv. 14, 1103–1111 (2017).PubMedCrossRef

125.

Dassau, E. et al. Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study. Diabetes Obes. Metab. 19, 1698–1705 (2017).PubMedCrossRef

126.

Lindpointner, S. et al. Use of the site of subcutaneous insulin administration for the measurement of glucose in patients with type 1 diabetes. Diabetes Care 33, 595–601 (2010).PubMedCrossRef

127.

Regittnig, W. et al. Periodic extraction of interstitial fluid from the site of subcutaneous insulin infusion for the measurement of glucose: a novel single-port technique for the treatment of type 1 diabetes patients. Diabetes Technol. Ther. 15, 50–59 (2013).PubMedPubMedCentralCrossRef

128.

Nørgaard, K., Shin, J., Welsh, J. B. & Gjessing, H. Performance and acceptability of a combined device for insulin infusion and glucose sensing in the home setting. J. Diabetes Sci. Technol. 9, 215–220 (2015).PubMedPubMedCentralCrossRef

129.

Haidar, A., Smaoui, M. R., Legault, L. & Rabasa-Lhoret, R. The role of glucagon in the artificial pancreas. Lancet Diabetes Endocrinol. 4, 476–479 (2016).PubMedCrossRef

130.

Haidar, A. et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 3, 595–604 (2015).PubMedCrossRef

131.

Russell, S. J. et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N. Engl. J. Med. 371, 313–325 (2014).PubMedPubMedCentralCrossRef

132.

Jackson, M. A. et al. Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas. Curr. Diab. Rep. 12, 705–710 (2012).PubMedPubMedCentralCrossRef

133.

Weinzimer, S. A. et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care 35, 1994–1999 (2012).PubMedPubMedCentralCrossRef

134.

Renukuntla, V. S., Ramchandani, N., Trast, J., Cantwell, M. & Heptulla, R. A. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. J. Diabetes Sci. Technol. 8, 1011–1017 (2014).PubMedPubMedCentralCrossRef

135.

Sherr, J. L. et al. Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide. Diabetes Care 39, 1127–1134 (2016).PubMedPubMedCentralCrossRef

136.

Malek, R. & Davis, S. N. Novel methods of insulin replacement: the artificial pancreas and encapsulated islets. Rev. Recent Clin. Trials 11, 106–123 (2016).PubMedCrossRef

137.

Rege, N. K., Phillips, N. F. B. & Weiss, M. A. Development of glucose-responsive ‘smart’ insulin systems. Curr. Opin. Endocrinol. Diabetes Obes. 24, 267–278 (2017).PubMedCrossRefPubMedCentral

138.

Valdes-Gonzalez, R. et al. Long-term follow-up of patients with type 1 diabetes transplanted with neonatal pig islets. Clin. Exp. Immunol. 162, 537–542 (2010).PubMedPubMedCentralCrossRef

139.

Elliott, R. B. et al. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation 14, 157–161 (2007).PubMedCrossRef

140.

Basta, G. et al. Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care 34, 2406–2409 (2011).PubMedPubMedCentralCrossRef

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Medicine Matters Diabetes

Abstract

Be confident that your patient care is up to date